PHB1 and non-small cell lung carcinoma: Among them, we learned that Bemcentinib has been currently studied for the treatment of non-small cell lung cancer, and the analysis results showed that Bemcentinib can bind to multiple ubiquitination sites (K202, K128, K177) of PHB1 with superior affinity (≤ -7).